US 12,084,511 B2
Peptide-based compounds for use in the prevention, treatment and/or detection of cancer
Edgar Schmitt, Mainz (DE); Horst Kunz, Mainz (DE); Natascha Stergiou, Mainz (DE); and Nikola Gaidzik, Heidelberg (DE)
Assigned to Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz (DE)
Appl. No. 16/982,095
Filed by Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz (DE)
PCT Filed Mar. 18, 2019, PCT No. PCT/EP2019/056672
§ 371(c)(1), (2) Date Sep. 18, 2020,
PCT Pub. No. WO2019/179923, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 18163057 (EP), filed on Mar. 21, 2018.
Prior Publication US 2021/0130489 A1, May 6, 2021
Int. Cl. C07K 16/30 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/3092 (2013.01) [A61P 35/00 (2018.01); C07K 2317/622 (2013.01)] 11 Claims
 
1. Peptide based compounds comprising:
a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2), and TFGNSFAY (SEQ ID NO: 3), and having an amino acid sequence as set forth in SEQ ID NO: 7, and
a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5), and ALWYSNHWV (SEQ ID NO: 6), and having an amino acid sequence as set forth in SEQ ID NO: 8,
wherein said peptide based compounds are capable of binding to tumour-associated Mucin-1 (TA-MUC1).